COMMUNIQUÉS West-GlobeNewswire

Crescendo Biologics to present at the 2024 AACR Annual Meeting
06/03/2024
Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted T cell enhancing [...]
ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024
06/03/2024
LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024, at 8:30 a.m. ET to report [...]
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
06/03/2024
- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) [...]
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
06/03/2024
Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show [...]
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
06/03/2024
GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today [...]
Psyence Biomedical’s Subsidiary, Psyence Australia, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study
06/03/2024
NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd ("Psyence [...]
Breckenridge Brewery Channels the Luck of The Irish With Nitro Irish Stout and Go Gold Sweepstakes
06/03/2024
Win a Trip for Two to Ireland LITTLETON, Colo., March 06, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery (“Breck Brew”) , a subsidiary of Tilray Brands, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY and TSX: TLRY), [...]
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
06/03/2024
Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional Superkine, MDNA113, will also be presented at the Annual Meeting TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna [...]
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
06/03/2024
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose cohort in Phase 1 trial [...]
Interactive Strength Inc. (Nasdaq: TRNR) to Exhibit Both CLMBR and FORME Lift at IHRSA in Los Angeles March 6-8
06/03/2024
CLMBR is Receiving Significant Interest From Gyms for use on the Cardio Floor and in the Group Fitness Room as a Replacement for Spin Bike FORME is Receiving the Highest Interest From Country Clubs and Multi-family [...]
Kamada Reports Strong Fiscal Year and Fourth Quarter 2023 Financial Results, and Provides Full-Year 2024 Guidance Representing Double-Digit Growth in Revenue and Profitability
06/03/2024
Total Revenues for Fiscal Year 2023 of $142.5 Million, Representing All-Time Record Annual Revenues and Up 10% Compared to Fiscal Year 2022 Fiscal Year 2023 Adjusted EBITDA of $24.1 Million, Up 35% Year-over-Year Strong [...]
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
06/03/2024
New translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation [...]
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
06/03/2024
In vivo Proof-of-Concept demonstrated for its off-the-shelf miCAR7 T-cell product, data presented at the 7 th CAR-TCR Summit Europe Milestone achieved in its collaboration with Allogene Therapeutics GENEVA, March 06, [...]
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
06/03/2024
ZUG, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks [...]
Cingulate to Attend DCAT Week 2024 in New York City
06/03/2024
Will Host Licensing Meetings with Multiple Parties to Discuss Assets, Pipeline and Technology KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing [...]
BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024
06/03/2024
MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024. [...]
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
06/03/2024
PARIS, March 06, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry [...]
Affimed Announces 1-for-10 Reverse Stock Split
06/03/2024
MANNHEIM, Germany, March 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight [...]
Nexstim Plc Publishes 2023 Annual Report
06/03/2024
Company announcement, Helsinki, 6 March 2024 at 1 PM (EET) Nexstim Plc Publishes 2023 Annual Report Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the publication of its 2023 Annual Report. These documents [...]

Pages